Company research
Dogwood Therapeutics, Inc.
CIK 1818844Updated Sep 29, 2026
SecurityDWTX · NASDAQ · equity
Name history
Virios Therapeutics, Inc. · through Oct 15, 2024Virios Therapeutics, LLC · through Dec 16, 2020
DWTX price & chart
Loading TradingView…
NASDAQ:DWTX on TradingView ↗About the company
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. Dogwood’s research pipeline includes two first-in-class development candidates, Halneuron® and SP16 IV. Our lead product candidate, Halneuron®, is in Phase 2b development to treat pain conditions including the neuropathic pain associated with chemotherapy treatment. Halneuron® has been granted fast track designation from the FDA for the treatment of CINP. Halneuron® is a non-opioid, NaV 1.7 analgesic which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP.
In the news
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results ↗
Recent filings
10-Q filing
SCHEDULE 13G/A filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 90,171,237Source | 94,308,246Source | 4,165,442Source | 8,369,756Source |
| Property, Plant and Equipment, NetUSD | 12,754Source | 16,811Source | — | — |
| GoodwillUSD | 12,401,118Source | 11,812,476Source | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 68,985,026Source | 65,710,527Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,524,744Source | 14,847,949Source | 3,316,946Source | 7,030,992Source |
| Assets, CurrentUSD | 8,431,206Source | 16,544,462Source | 4,165,442Source | 8,369,756Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,906,462Source | 1,696,513Source | 848,496Source | 1,338,764Source |
| Operating Lease, Right-of-Use AssetUSD | 163,140Source | 205,837Source | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 15,274,370Source | 30,027,223Source | 358,548Source | 1,043,262Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 2,974Source | 133Source | 1,926Source | 1,833Source |
| Additional Paid in CapitalUSD | 183,856,376Source | 67,856,589Source | 65,573,300Source | 63,497,868Source |
| Retained Earnings (Accumulated Deficit)USD | -108,076,316Source | -73,818,946Source | -61,469,222Source | -56,173,207Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -587,039Source | -3,862,987Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 74,896,867Source | -10,124,339Source | 3,806,894Source | 7,326,494Source |
| Liabilities and EquityUSD | 90,171,237Source | 94,308,246Source | 4,165,442Source | 8,369,756Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,059,203Source | 3,176,336Source | 358,548Source | 1,043,262Source |
| Operating Lease, Liability, CurrentUSD | 56,841Source | 49,696Source | — | — |
| Accounts Payable, CurrentUSD | 760,945Source | 1,231,805Source | 111,913Source | 573,164Source |
| Operating Lease, Liability, NoncurrentUSD | 105,763Source | 154,885Source | — | — |
| Deferred Income Tax Liabilities, NetUSD | 12,109,404Source | 11,314,925Source | 215,622Source | 340,865Source |
| Other Liabilities, NoncurrentUSD | — | 15,381,077Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,241,417Source | 1,894,835Source | 246,635Source | 470,098Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -34,257,370Source | -12,349,724Source | -5,296,015Source | -12,247,834Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 355,642Source | 476,021Source | 619,972Source | 582,659Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -532,607Source | 219,888Source | -461,251Source | 219,301Source |
| Deferred Income Tax Expense (Benefit)USD | 221,096Source | -503Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -15,618,651Source | -8,790,805Source | -4,870,489Source | -11,467,797Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 3,761,936Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 7,284,806Source | 16,704,464Source | 1,156,443Source | 4,490,605Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 6,524,744Source | 14,847,949Source | 3,316,946Source | 7,030,992Source |
| Additional Financial Items | ||||
| Amortization of Debt Issuance CostsUSD | 52,373Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | 58,432Source | — | — |
| DepreciationUSD | 2,063Source | 12,177Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -27,916Source | -30,787Source | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -27,916Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -2,731Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | -6,134,120Source | — | — | — |
| General and Administrative ExpenseUSD | 6,102,374Source | 8,696,335Source | 3,718,841Source | 4,245,681Source |
| GoodwillUSD | 12,401,118Source | 11,812,476Source | — | — |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | 221,096Source | -503Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -34,257,370Source | -12,349,724Source | -5,296,015Source | -12,247,834Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -35,514,032Source | -12,863,829Source | — | — |
| Noncash Merger Related CostsUSD | — | 3,563,273Source | — | — |
| Operating ExpensesUSD | 27,968,445Source | 12,227,248Source | 5,446,919Source | 12,315,309Source |
| Other Nonoperating Income (Expense)USD | -6,067,829Source | -122,979Source | 150,904Source | 67,475Source |
| Proceeds from Issuance of Common StockUSD | — | — | 1,156,443Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -27,968,445Source | -12,227,248Source | -5,446,919Source | -12,315,309Source |
| Other Nonoperating Income (Expense)USD | -6,067,829Source | -122,979Source | 150,904Source | 67,475Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -34,036,274Source | -12,350,227Source | -5,296,015Source | -12,247,834Source |
| Income Tax Expense (Benefit)USD | 221,096Source | -503Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -34,257,370Source | -12,349,724Source | -5,296,015Source | -12,247,834Source |
| Earnings Per Share, BasicUSD per share | -7.13Source | -12.52Source | -0.28Source | -1.11Source |
| Earnings Per Share, DilutedUSD per share | -7.13Source | -12.52Source | -0.28Source | -1.11Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,977,446Source | 1,027,788Source | 18,776,790Source | 11,070,116Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,977,446Source | 1,027,788Source | 18,776,790Source | 11,070,116Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -27,916Source | -30,787Source | — | — |
| General and Administrative ExpenseUSD | 6,102,374Source | 8,696,335Source | 3,718,841Source | 4,245,681Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Interest Income (Expense), NetUSD | — | — | 150,904Source | 67,475Source |
| Interest Income (Expense), Nonoperating, NetUSD | 96,938Source | -92,192Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -35,514,032Source | -12,863,829Source | — | — |
| Operating ExpensesUSD | 27,968,445Source | 12,227,248Source | 5,446,919Source | 12,315,309Source |
| Research and Development ExpenseUSD | 21,866,071Source | 3,530,913Source | 1,728,078Source | 8,069,628Source |
Filing attachments
dwtx-20260813xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 dwtx-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled - - Commencement of Phase 2b Long-Term Extension Study to assess Halneuron® reduction in pain over three months of treatment - - Appointment of Iain Dukes, D.Phil., Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - - A…
Read attachment ↗dwtx-20260514xex99d1.htm · 8-K · 2026-05-14
EX-99.1 2 dwtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy - - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Do…
Read attachment ↗dwtx-20260326xex99d1.htm · 8-K · 2026-03-26
EX-99.1 2 dwtx-20260326xex99d1.htm EX-99.1 CEO Letter to Dogwood Therapeutics Shareholders: First Quarter 2026 Progress Report ALPHARETTA, Ga., March 26, 2026 -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a development-stage biotechnology company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today issued a corporate update in the following Letter to Shareholders from CEO Greg Duncan. Dear Shareholders, Dogwood Therapeutics is a de…
Read attachment ↗dwtx-20260318xex99d1.htm · 8-K · 2026-03-18
EX-99.1 2 dwtx-20260318xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results ATLANTA, Ga., March 18, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025. “The Company continues to execute at a high level, including recruitmen…
Read attachment ↗dwtx-20260120xex99d1.htm · 8-K · 2026-01-20
EX-99.1 2 dwtx-20260120xex99d1.htm EX-99.1 Exhibit 99.1 CEO Letter to Dogwood Therapeutics Shareholders: The Year in Review, The Year Ahead ALPHARETTA, Ga., January 20, 2026 -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, issues a corporate update in the following Letter to Shareholders from CEO, Greg Duncan. Dear Shareholders, Dogwood Therapeutics is a development-stage biotec…
Read attachment ↗dwtx-20260109xex99d1.htm · 8-K · 2026-01-13
EX-99.1 8 dwtx-20260109xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development Pricing of $12. 5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules. Alpharetta, GA January 12, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) ("DWTX" or "Company"), a company that focuses on developing new non-opioid medicines …
Read attachment ↗